Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: histone deacetylase inhibitors - BioMarin

Next Previous
Search
Drug Profile

Research programme: histone deacetylase inhibitors - BioMarin

Alternative Names: BMN-290; HDAC inhibitors - BioMarin

Latest Information Update: 28 Nov 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Repligen Corporation
  • Developer BioMarin Pharmaceutical; Repligen Corporation
  • Class Small molecules
  • Mechanism of Action Histone deacetylase inhibitors; Transcription factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Friedreich's ataxia; Huntington's disease
  • Discontinued Cognition disorders; Spinal muscular atrophy

Most Recent Events

  • 28 Nov 2021 No recent reports of development identified for preclinical development in Friedreich's ataxia in USA (PO)
  • 25 Oct 2018 BioMarin announces intention to submit IND for BMN 290 for Freidriech's ataxia in the first half of 2019
  • 26 Oct 2017 Preclinical trials in Friedreich's ataxia in USA (PO)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top